BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05907291 (CRN04894 in Congenital Adrenal Hyperplasia): BVCT ex-ante prediction vs. reported outcome

On 14 Aug 2023, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 3 Jun 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05907291
Acronym
TouCAHn
Drug Name
CRN04894
Drug MoA
oral ACTH MC2R antagonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Urogenital Diseases
Indication
Congenital Adrenal Hyperplasia (CAH)
Human Patients
30
Sponsor
Crinetics Pharmaceuticals
Phase
Phase 2

Prediction of , index 1208

Prospective Prediction
Prediction Index
1208
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
294 days in advance
Readout Data Interpretation
100% A4 normal for CAH.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Phase
Phase 2
Status
Completed
Enrollment
38
Lead sponsor
Crinetics Pharmaceuticals Inc.
Conditions
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Interventions
DRUG: atumelnant (CRN04894)
Design
Sequential · None
Primary purpose
Treatment
Start
2023-07-03
Primary completion
2025-08-22
Completion
2025-08-22
Results first posted
2026-09-10
Primary outcomes
  • Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) PM Dosing (Baseline and Week 12)
  • Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) AM Dosing (Baseline and Week 12)
  • Number of Participants Reporting of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events Leading to Discontinuation Throughout the Study (From Day 1 to Up to Week 16 (End of study))

NCT05907291 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials